Patents by Inventor Jaan A. Pesti

Jaan A. Pesti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the preparation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2, 1-F][1,2,4]triazin-6-yloxy]-1-methylethyl ester
    Patent number: 7671199
    Abstract: The invention relates to an improved process for preparing [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester of the formula: Compound I has been shown to be useful for the treatment of certain types of cancer.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: March 2, 2010
    Assignee: Britsol-Myers Squibb Company
    Inventors: Gerard A. Crispino, Mourad Hamedi, Thomas L. LaPorte, John E. Thornton, Jaan A. Pesti, Zhongmin Xu, Paul C. Lobben, David K. Leahy, Jale Muslehiddinoglu, Chiajen Lai, Lori Ann Spangler, Robert P. Discordia, Francis S. Gibson
  • Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
    Patent number: 7442792
    Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: October 28, 2008
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James P. Sherbine, Shawn K. Pack, Jaan A. Pesti, Robert E. Yule, Kenneth C. McNulty
  • PROCESS FOR THE PREPARATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TRIAZIN-6-YLOXY]-1-METHYLETHYL ESTER
    Publication number: 20070249610
    Abstract: The invention relates to an improved process for preparing [(1R),2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester of the formula: Compound I has been shown to be useful for the treatment of certain types of cancer.
    Type: Application
    Filed: April 20, 2007
    Publication date: October 25, 2007
    Inventors: Gerard Crispino, Mourad Hamedi, Thomas LaPorte, John Thornton, Jaan Pesti, Zhongmin Xu, Paul Lobben, David Leahy, Jale Muslehiddinoglu, Chiajen Lai, Lori Spangler, Robert Discordia
  • Process for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
    Publication number: 20070161790
    Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression.
    Type: Application
    Filed: March 13, 2007
    Publication date: July 12, 2007
    Inventors: James Sherbine, Shawn Pack, Jaan Pesti, Robert Yule, Kenneth McNulty
  • Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
    Patent number: 7208596
    Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: April 24, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: James P. Sherbine, Shawn K. Pack, Jaan A. Pesti, Robert E. Yule, Kenneth C. McNulty
  • Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
    Publication number: 20050143380
    Abstract: The present invention provides novel processes and intermediates for preparing corticotropin releasing factor (CRF) receptor antagonists having the structure below which are useful in treating CRF-related disorders such as anxiety and depression.
    Type: Application
    Filed: November 10, 2004
    Publication date: June 30, 2005
    Inventors: James Sherbine, Shawn Pack, Jaan Pesti, Robert Yule, Kenneth McNulty
  • Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester
    Patent number: 6624311
    Abstract: The present invention relates to a process for the enantioselective enzymatic aminolysis of racemic 2-[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]acetate ((R/S)-I) by methyl N&agr;-Boc-L-&agr;,&bgr;-diaminoproprionate.p-toluenesulfonic acid. More specifically, this invention pertains to a process for the enantioselective enzymatic aminolysis of racemic isobutyl 2-[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]-acetate by methyl N&agr;-Boc-L-&agr;,&bgr;-diaminoproprionate.p-toluene sulfonic acid to produce (R)-methyl-3-[[[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine, an intermediate in the preparation of roxifiban, an isoxazoline-based platelet glycoprotein IIb/IIIa antagonist which has activity as an antithrombotic agent.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: September 23, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Robert DiCosimo, Philip Ma, Jaan A. Pesti
  • Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester
    Publication number: 20020160465
    Abstract: The present invention relates to a process for the enantioselective enzymatic aminolysis of racemic 2-[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]acetate ((R/S)-I) by methyl N&agr;-Boc-L-&agr;,&bgr;-diaminoproprionate .p-toluenesulfonic acid. More specifically, this invention pertains to a process for the enantioselective enzymatic aminolysis of racemic isobutyl 2-[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]-acetate by methyl N&agr;-Boc-L-&agr;,&bgr;-diaminoproprionate .p-toluene sulfonic acid to produce (R)-methyl-3-[[[3-(4-cyanophenyl)-4,5-dihydro-5-isoxazolyl]acetyl]amino]-N-(butoxycarbonyl)-L-alanine, an intermediate in the preparation of roxifiban, an isoxazoline-based platelet glycoprotein IIb/IIIa antagonist which has activity as an antithrombotic agent.
    Type: Application
    Filed: October 25, 2001
    Publication date: October 31, 2002
    Inventors: Robert DiCosimo, Philip Ma, Jaan A. Pesti
  • Crystalline roxifiban
    Patent number: 6306886
    Abstract: The potent platelet glycoprotein IIb/IIIa antagonist, roxifiban, is produced in crystalline form. Crystalline roxifiban exists in two polymorphic forms, designated Form 1 and Form 2. These polymorphic forms are characterized by x-ray powder diffraction and solid-state carbon NMR. Pharmaceutical compositions and methods for the treatment or prevention of diseases mediated by platelet aggregation are described.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: October 23, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Michael Blaise Maurin, Philip Ma, David John Meloni, Jaan A. Pesti, Lucius Thomas Rossano, Randall K. Ward, Jianguo Yin, Lin Hua Zhang, Goss S. Kauffman
  • Crystalline 10,10-Bis((2-fluoro-4-pyridinyl)methyl)-9(10H)-Anthracenone and an improved process for preparing the same
    Patent number: 6214847
    Abstract: The present invention relates to processes for the synthesis of a crystalline polymorph of 10,10-Bis((2-fluoro-4-pyridinyl)methyl)-9(10H)-Anthracenone in high purity. The product is useful in the synthesis of pharmaceutical compounds for the reduction of cholinergic system dysfunction.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: April 10, 2001
    Assignee: Dupont Pharmaceuticals Company
    Inventors: Jaan A. Pesti, Joseph M. Fortunak, George F. Huhn, Michael Maurin, Jianguo Yin
  • Dynamic resolution of isoxazoline thioesters to isoxazoline carboxylic acids
    Patent number: 6022977
    Abstract: The present invention relates generally to a novel method for preparation of substituted isoxazolin-5-yl acetic acid in high optical purity from a stereoisomeric mixture of an esterified substituted isoxazolin-5-yl acetate. The products are useful in the synthesis of compounds for pharmaceuticals, especially the treatment of thrombolytic disorders, and agricultural products.
    Type: Grant
    Filed: March 25, 1998
    Date of Patent: February 8, 2000
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Lin-Hua Zhang, Luigi Anzalone, Jaan A. Pesti, Jianguo Yin